Bad Blood (2018) is the harrowing inside story of a how a tech start-up rooted in Silicon Valley’s fake-it-till-you-make-it culture risked the lives of millions with a blood-testing device that proved too good to be true. Written by Pulitzer-winning journalist John Carreyrou, who broke the story and pursued it to its end, this is the account of Theranos and its wunderkind CEO Elizabeth Holmes’ meteoric rise and epic fall from grace.
John Carreyrou is an investigative journalist and recipient of two Pulitzer prizes for his articles in the Wall Street Journal. His previous scoops include reports documenting the fall of Vivendi Universal and US–French relations during the Iraq War.
Upgrade to Premium now and get unlimited access to the Blinkist library. Read or listen to key insights from the world’s best nonfiction.
Upgrade to PremiumThe Blinkist app gives you the key ideas from a bestselling nonfiction book in just 15 minutes. Available in bitesize text and audio, the app makes it easier than ever to find time to read.
Start free trialGet unlimited access to the most important ideas in business, investing, marketing, psychology, politics, and more. Stay ahead of the curve with recommended reading lists curated by experts.
Start free trialBad Blood (2018) is the harrowing inside story of a how a tech start-up rooted in Silicon Valley’s fake-it-till-you-make-it culture risked the lives of millions with a blood-testing device that proved too good to be true. Written by Pulitzer-winning journalist John Carreyrou, who broke the story and pursued it to its end, this is the account of Theranos and its wunderkind CEO Elizabeth Holmes’ meteoric rise and epic fall from grace.
Like many people, Elizabeth Holmes was scared of needles.
It was this fear which gave her a great idea: a wearable patch which would test patients’ blood over the course of a day using microneedles.
Build that, she thought, and you’d not only do away with the need for needles but you’d also have a device which could provide real-time information on bloodwork to assist ongoing diagnoses.
By 2004, she was ready to start putting her idea into practice. She founded Theranos with Shaunak Roy, one of her peers at Stanford University.
But there was a snag. The pair soon realized that microneedles wouldn’t be able to draw enough blood. That’s when the original idea started to take on a new shape.
Their next idea was a credit-card-sized blood-testing machine which would draw a few drops of blood using a pinprick. That device could then be plugged into another, slightly larger gadget which would run diagnostic tests.
The second, toaster-sized machine would perform chemical and conductivity tests to check for 240 common ailments. These ranged from vitamin D deficiency to herpes and HIV.
It was a machine that promised to revolutionize healthcare – if it could be built. Medical diagnostic tools would suddenly be at the fingertips of millions of people.
The duo started imagining a world in which everyone had a Theranos device in his or her home. Thousands of lives would be saved thanks to early diagnoses.
The machine could monitor hormone levels and forward the information to healthcare professionals on an hourly or daily basis. Doctors could then advise patients to take extra pills or call an ambulance.
Poor people would suddenly have access to cheap medical care. After all, the device would cut out the need for expensive doctors and nurses!
A blood test would become something anyone could have done while they were out shopping for no more than ten or twenty dollars.
The possibilities seemed endless.
What would happen if, say, you dispatched the machines to war zones or set them up in field hospitals in the wake of natural disasters? You could even have one in the back of an army jeep.